Log In
BCIQ
Print this Print this
 

MORAb-022

  Manage Alerts
Collapse Summary General Information
Company Eisai Co. Ltd.
DescriptionHuman IgG1 mAb
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today